Targeting <scp>IL</scp>‐23 by employing a p40 peptide‐based vaccine ameliorates murine allergic skin and airway inflammation

Abstract

Administration of an IL-23p40 peptide-based vaccine down-regulates allergic skin and airway inflammation, suggesting that this strategy may be a potential therapeutic approach in the treatment of AD and asthma.